Eli Lilly and Company $LLY Shares Purchased by Summit Wealth & Retirement Planning Inc.

Summit Wealth & Retirement Planning Inc. boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 67.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,004 shares of the company’s stock after buying an additional 406 shares during the quarter. Summit Wealth & Retirement Planning Inc.’s holdings in Eli Lilly and Company were worth $783,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company in the 1st quarter valued at approximately $27,000. Blume Capital Management Inc. grew its holdings in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after purchasing an additional 14 shares during the last quarter. IMG Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the second quarter valued at $35,000. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company in the first quarter valued at $40,000. Finally, TD Capital Management LLC raised its stake in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 4,314 shares of company stock valued at $2,766,929. Insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of research reports. Berenberg Bank reissued a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. UBS Group increased their price target on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a research report on Friday. Guggenheim restated a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 16th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Daiwa Capital Markets cut Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target for the company. in a report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $960.88.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $923.35 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $955.46. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a 50 day moving average price of $799.97 and a 200 day moving average price of $775.76. The company has a market cap of $872.92 billion, a price-to-earnings ratio of 60.35, a PEG ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the firm posted $1.18 earnings per share. Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s payout ratio is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.